X

Trial Profile

A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Phase III Study of MRA-SC in Patients with Takayasu Arteritis

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 07 Dec 2021

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Tocilizumab (Primary) ; Glucocorticoids
Indications Takayasu syndrome
Focus Therapeutic Use
Acronyms TAKT study
Sponsors Chugai Pharmaceutical

Most Recent Events

05 Jun 2021 Results post hoc analysis (n=28) evaluating vascular imaging in patients with refractory takayasu arteritis, presented at the 22nd Annual Congress of the European League Against Rheumatism
17 Jan 2020 Results assessing Long-term efficacy and safety of tocilizumab in refractory Takayasu arteritis published in the Rheumatology
09 Feb 2018 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com